Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims
- PMID: 20095797
- DOI: 10.1185/03007990903579171
Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims
Abstract
Objective: This study explored physicians' perceptions of patient adherence to medications compared with patient adherence derived by administrative data in the treatment of osteoporosis.
Research design and methods: A study involving written questionnaires from prescribers treating patients with postmenopausal osteoporosis (PMO) compared the questionnaire responses to pharmacy claims of these prescribers' patients' refill patterns. Approximately 2000 physicians from a large US health plan were faxed or mailed a survey. Data from the physician survey were merged with administrative claims data of the participating physicians' patients.
Results: A total of 412 physicians (21.8%) responded. Although a low response rate, there were no significant demographic differences between participating and non-participating physicians. Surveyed physicians reported that 66% of their patients had private/commercial coverage and over 60% reported seeing their PMO patients annually. Overall, physicians estimated that 69.2% of patients were adherent 80% of the time after 12 months of therapy. Yet, pharmacy claims data for those physicians' patients indicated 48.7% of patients were adherent (defined as having an MPR of >or=80%) after 12 months of therapy. Physicians overestimated their patients' adherence regardless of medication class and across physician specialties. Regression modeling revealed that physicians who have been in practice longer estimated fewer patients as adherent, whereas those who prescribe more PMO treatments estimate a greater number of patients as adherent. Providers cited side effects and affordability of medication as the most frequent reasons for non-adherence.
Conclusions: Physicians overestimate patient adherence to PMO therapies. Improving physician awareness of medication non-adherence to PMO therapies may facilitate physician-patient dialogue, with the aim of identifying patient-centered reasons for non-adherence. These discussions are important because patients with poorer adherence have a higher risk of fracture. Future research should focus on reasons for patient non-adherence to osteoporosis regimens and intervention strategies that improve communication between the provider and patient. Findings must be considered within the limitations of this claims database analysis. Some degree of incomplete or incorrect coding may exist, and the presence of a claim for a filled prescription does not indicate that the medication was consumed or taken as prescribed. Patients included in the study are not necessarily representative of all patients being treated for osteoporosis.
Similar articles
-
The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.Curr Med Res Opin. 2007 Dec;23(12):3137-52. doi: 10.1185/030079907X242890. Curr Med Res Opin. 2007. PMID: 17988435
-
Adherence and persistence in patients with severe osteoporosis treated with teriparatide.Curr Med Res Opin. 2010 Mar;26(3):675-81. doi: 10.1185/03007990903538409. Curr Med Res Opin. 2010. PMID: 20078188 Clinical Trial.
-
Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.Clin Ther. 2009 Nov;31(11):2584-607. doi: 10.1016/j.clinthera.2009.11.030. Clin Ther. 2009. PMID: 20110004
-
Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Postgrad Med. 2011 Mar;123(2):131-44. doi: 10.3810/pgm.2011.03.2271. Postgrad Med. 2011. PMID: 21474901 Review.
-
How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.Ann Pharmacother. 2006 Jun;40(6):1143-50. doi: 10.1345/aph.1G534. Epub 2006 May 30. Ann Pharmacother. 2006. PMID: 16735667 Review.
Cited by
-
Improving drug adherence in osteoporosis: an update on more recent studies.Ther Adv Musculoskelet Dis. 2018 Jul;10(7):141-149. doi: 10.1177/1759720X18785539. Epub 2018 Jul 10. Ther Adv Musculoskelet Dis. 2018. PMID: 30023009 Free PMC article. Review.
-
Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.BMJ Open. 2019 Apr 14;9(4):e027049. doi: 10.1136/bmjopen-2018-027049. BMJ Open. 2019. PMID: 30987990 Free PMC article.
-
The SPUR Model: A Framework for Considering Patient Behavior.Patient Prefer Adherence. 2020 Jan 16;14:97-105. doi: 10.2147/PPA.S237778. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32021121 Free PMC article.
-
Osteoporosis medication adherence: physician perceptions vs. patients' utilization.Bone. 2013 Jul;55(1):1-6. doi: 10.1016/j.bone.2013.03.003. Epub 2013 Mar 15. Bone. 2013. PMID: 23502042 Free PMC article.
-
If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.Ther Clin Risk Manag. 2011;7:181-98. doi: 10.2147/TCRM.S17513. Epub 2011 May 24. Ther Clin Risk Manag. 2011. PMID: 21691589 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical